�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.
.
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
.
.

.
.